280 A phase 2 randomized clinical trial of serlopitant, a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa

Abstract

Chronic itch is one of the most frequently reported symptoms in patients with epidermolysis bullosa (EB). We hypothesized that a neurokinin-1 receptor antagonist (NK1RA) which targets the substance P pathway can reduce EB-related itch. In 2019, we reported on the safety of a NK1R antagonist, serlopitant, in a pilot study. Here we report the phase 2 randomized, double-blind, placebo-controlled trial evaluating serlopitant 5mg PO daily for 8 weeks versus placebo for EB-related pruritus. The double-blind phase was followed by a 4-week washout and optional open label extension.